PEPTIDESTAT
InvestigationalWeight lossSubcutaneousEvidence 4/5

Retatrutide

Also known as: LY3437943

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

Read guideBuy / compare source
Retatrutide
Drug class
Triple agonist (GLP-1 / GIP / glucagon)
Primary targets
GLP-1R, GIPR, GCGR
Dose reference
1–12 mg once weekly (trial)
Half-life
~6 days
Developer / origin
Eli Lilly
Reference year
2023
Evidence score
4/5 - Phase 2 human evidence
Evidence 4/5

Phase 2 human evidence

Retatrutide has randomized phase 2 human data in obesity and type 2 diabetes, but it remains investigational and is not an approved drug.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • Human phase 2 obesity trial
  • Human type 2 diabetes phase 2 trial
  • No approved indication yet

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Retatrutide guides

Read the matching guide or adjacent research pages for more context.

Retatrutide: What the Research Actually ShowsRetatrutide is an investigational triple-agonist peptide drawing major attention for weight loss. Here's what the clinical research actually shows.Retatrutide Dosing in Clinical Trials: How It's StructuredHow retatrutide dosing was structured in published trials — escalation schedules, the dose ranges studied, and why titration matters.GLP-1 for Weight Loss: The 2026 Complete GuideGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. Here's how to think about them honestly — eligibility, results, cost, side effects, and what happens when you stop.What Is GLP-1? Complete Guide to the Hormone, the Drugs, and What They DoGLP-1 is a hormone your gut releases after eating. GLP-1 agonist drugs amplify its effect — slowing digestion, reducing appetite and improving blood sugar. This is the complete guide.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Details

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Details

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Details
4/5
Weight lossInvestigational

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Details

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.